Seritage Growth Properties
Real Estate
Seritage Growth Properties (SRG) Stock News
The latest SRG headlines and market coverage — 6 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
Intuitive Surgical, Inc. (ISRG) Gains As Market Dips: What You Should Know
Intuitive Surgical (ISRG) gained 2.41% to $414.52 on October 7, 2026, outperforming a declining market. The stock has surged 15.59% over the past month, significantly outpacing the Medical sector's 4.73% loss. Upcoming earnings on October 20 are expected to show 8.75% EPS growth and 14.98% revenue growth year-over-year. However, the stock carries a Zacks Rank #3 (Hold) rating with a premium Forward P/E of 37.71 versus the industry average of 23.11.
- Zacks Investment Research·
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
Intuitive Surgical's single-port (SP) platform is emerging as a significant growth franchise with 61% year-over-year procedure growth and an installed base of 445 systems. Strong U.S. utilization gains (25% YoY) and expanding stapler adoption (nearly 60% of eligible cases) support the platform's trajectory toward becoming a billion-dollar business. The company is also expanding internationally and through product innovation.
- Zacks Investment Research·
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
Intuitive Surgical published a large meta-analysis in Annals of Surgery Open showing da Vinci robotic-assisted surgery delivered significant perioperative improvements across 13 benign procedures compared to laparoscopic and open surgery. Results included 54% lower conversion to open surgery, 69% reduction in blood transfusions versus open surgery, and 46% fewer 30-day complications. The da Vinci 5 platform continues gaining momentum with over 1,700 systems installed. ISRG stock gained ~8% following the announcement and currently holds a Zacks Rank #3 (Hold).
- Zacks Investment Research·Neutral
Intuitive Surgical, Inc. (ISRG) Rises As Market Takes a Dip: Key Facts
Intuitive Surgical (ISRG) gained 2.38% to $377.94 on September 14, 2026, outperforming a declining broader market. The company is expected to report EPS of $2.61 (up 8.75% YoY) and quarterly revenue of $2.88 billion (up 14.98% YoY). However, the stock has declined 6.43% over the past month and carries a Zacks Rank #3 (Hold) rating with a premium valuation at 34.39 Forward P/E versus the industry average of 21.78.
- Zacks Investment Research·
The Zacks Analyst Blog Highlights FANUY, ABBNY, KYCCF, NVDA, ISRG, ILMN, NOVT, BOTZ, ROBO, ROBT and IBOT
Zacks highlights the robotics and AI sector as a major growth opportunity, with the general-purpose robotics market projected to grow from under $1 billion in 2025 to $370 billion by 2040. The article examines key industry players including Fanuc, ABB, Keyence, NVIDIA, Intuitive Surgical, and Illumina, and recommends four robotics-focused ETFs (BOTZ, ROBO, ROBT, IBOT) as diversified investment vehicles to capitalize on this trend.
- Zacks Investment Research·
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical is prioritizing R&D investment over near-term profitability to drive long-term growth, focusing on AI/ML, robotics, and expanding into new clinical areas like GI, cardiac, and lung procedures. The company is sacrificing near-term expense leverage to build competitive moats and broaden its addressable market. Peer companies Edwards Lifesciences and Glaukos are similarly investing heavily in R&D to strengthen their competitive positions.